Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 8, 2025

MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
MongoDB and Bath & Body Works have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – December 8, 2025 – Zacks Equity Research shares MongoDB MDB as the Bull of the Day and Bath & Body Works, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 sales were down in the high single digits

    80% confidence
  • Performance would have been worse had it not been for an extended fall sale

    80% confidence
  • North American consumers are spending less on non-essential home products

    80% confidence
  • Bath & Body Works' core demand engine is weakening, signaling erosion in brand relevance and consumer engagement

    80% confidence
  • MongoDB has surpassed Zacks Consensus Analyst Estimates by 69.30% over the past four quarters

    80% confidence
  • Company expects EPS growth of ~30% and revenue growth of 20%

    80% confidence
  • MDB shares are a buy

    80% confidence
  • Zacks Consensus Analyst Estimates suggest negative earnings growth over the next two years for Bath & Body Works

    80% confidence
  • Top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year since 2000

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com